Portal de Periódicos da CAPES

Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle

2000; Wiley; Volume: 23; Issue: 4 Linguagem: Inglês

10.1002/(sici)1097-4598(200004)23

1097-4598

Richard J. Zeman, Hong Peng, M. J. Danon, Joseph D. Etlinger,

Pharmacological Effects and Assays

Muscle & NerveVolume 23, Issue 4 p. 521-528 Main Article Clenbuterol reduces degeneration of exercised or aged dystrophic (mdx) muscle Richard J. Zeman PhD, Corresponding Author Richard J. Zeman PhD [email protected] Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USADepartment of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USASearch for more papers by this authorHong Peng MD, Hong Peng MD Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USASearch for more papers by this authorM. Jak Danon MD, M. Jak Danon MD Department of Neurology, New York Medical College, Valhalla, New York, USASearch for more papers by this authorJoseph D. Etlinger PhD, Joseph D. Etlinger PhD Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USASearch for more papers by this author Richard J. Zeman PhD, Corresponding Author Richard J. Zeman PhD [email protected] Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USADepartment of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USASearch for more papers by this authorHong Peng MD, Hong Peng MD Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USASearch for more papers by this authorM. Jak Danon MD, M. Jak Danon MD Department of Neurology, New York Medical College, Valhalla, New York, USASearch for more papers by this authorJoseph D. Etlinger PhD, Joseph D. Etlinger PhD Department of Cell Biology and Anatomy, New York Medical College, Valhalla, New York 10595, USASearch for more papers by this author First published: 14 March 2000 https://doi.org/10.1002/(SICI)1097-4598(200004)23:4 3.0.CO;2-8Citations: 35AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract Evidence of dystrophic muscle degeneration in the hind limb muscles of young (20-week-old) treadmill-exercised or aged (87-week-old) sedentary mdx mice was greatly reduced by treatment with clenbuterol, a β2-adrenoceptor agonist. Daily treadmill exercise for 10 weeks increased the size of regions within the mdx plantaris but not the soleus or gastrocnemius muscles, in which necrotic muscle fibers or the absence of fibers was observed. Clenbuterol reduced the size of these abnormal regions from 21% of total muscle cross-sectional area to levels (4%) found in sedentary mdx mice. In addition, the muscles obtained from aged clenbuterol-treated mdx or wild-type mice did not display the extensive fibrosis or fiber loss observed in untreated mdx mice. These observations are consistent with a mechanism of dystrophic muscle degeneration caused by work load–induced injury that is cumulative with aging and is opposed by β2-adrenoceptor activation. Optimization of β2-agonist treatment of muscular dystrophy in mdx mice may lead to a useful therapeutic modality for human forms of the disease. © 2000 John Wiley & Sons, Inc. Muscle Nerve 23: 521–528, 2000. REFERENCES 1Agbenyega ET, Wareham AC. Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol 1992; 102A: 141–145. 10.1016/0300-9629(92)90026-M Web of Science®Google Scholar 2Bardsley RG, Allcock MMJ, Dawson JM, Dumelow NW, Higgins JA, Lasslett YV, Lockley AK, Parr T, Buttery PJ. Effect of β-agonist on expression of calpain and calpastatin activity in skeletal muscle. Biochimie 1992; 74: 267–273. 10.1016/0300-9084(92)90125-X CASPubMedWeb of Science®Google Scholar 3Bowman WC. Effects of adrenergic activators and inhibitors on the skeletal muscles. In: L Serkeres, editor. Handbook of experimental pharmacology, vol 54/II. Berlin: Springer Verlag; 1980. p 47–128. Google Scholar 4Brussee V, Tardif F, Tremblay JP. Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice. Neuromusc Disord 1997; 7: 487–492. 10.1016/S0960-8966(97)00115-6 CASPubMedWeb of Science®Google Scholar 5Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J 1996; 15: 1753–1765. 10.1002/j.1460-2075.1996.tb00524.x CASPubMedWeb of Science®Google Scholar 6Dick J, Vrbova G. Progressive deterioration of muscles in mdx mice induced by overload. Clin Sci 1993; 84: 145–150. 10.1042/cs0840145 CASPubMedWeb of Science®Google Scholar 7Dupont-Versteegden EE. Exercise and clenbuterol as strategies to decrease the progression of muscular dystrophy in mdx mice. J Appl Physiol 1996; 80: 734–741. CASPubMedWeb of Science®Google Scholar 8Dupont-Versteegden EE, Katz MS, Carter RJ. Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. Muscle Nerve 1995; 18: 1447–1459. 10.1002/mus.880181216 CASPubMedWeb of Science®Google Scholar 9Dupont-Versteegden EE, McCarter RJ, Katz MS. Voluntary exercise decreases progression of muscular dystrophy in diaphragm of mdx mice. J Appl Physiol 1994; 77: 1736–1741. 10.1152/jappl.1994.77.4.1736 CASPubMedWeb of Science®Google Scholar 10Fong Y, Moldawer LL, Marano M, Wei H, Barber A, Manogue K, Tracey KJ, Kuo G, Fischman DA, Cerami A. Cachectin/TNF or IL-1α induces cachexia with redistribution of body proteins. Am J Physiol 1989; 256: R659–R665. CASPubMedWeb of Science®Google Scholar 11Griggs RC, Moxley III RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, Cwik VA, Pandya S, Robison J, King W, Signore L, Schierbecker J, Florence J, Matheson-Burden N, Wilson B. Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology 1993; 43: 520–527. 10.1212/WNL.43.3_Part_1.520 CASPubMedWeb of Science®Google Scholar 12Hayes A, Williams DA. Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice. Clin Exp Pharmacol Physiol 1994; 21: 757–765. 10.1111/j.1440-1681.1994.tb02443.x CASPubMedWeb of Science®Google Scholar 13Hoffman EP, Knudson CM, Campbell KP, Kunkel LM. Subcellular fractionation of dystrophin to the triads of skeletal muscle. Nature 1987; 330: 754–758. 10.1038/330754a0 CASPubMedWeb of Science®Google Scholar 14Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byrnes T, Wang JC, Hsiao JC. Strength and endurance in the therapeutic evaluation of prednisolone-treated mdx mice. Res Commun Chem Pathol Pharmacol 1993; 79: 45–60. CASPubMedWeb of Science®Google Scholar 15Karpati G, Carpenter S, Prescott S. Small-caliber skeletal muscle fibers do not suffer necrosis in mdx mouse dystrophy. Muscle Nerve 1988; 11: 795–803. 10.1002/mus.880110802 CASPubMedWeb of Science®Google Scholar 16Kissel JT, Mendell JR, Griggs R, McDermett M, Tawil R. Open-label clinical trial of albuterol in facioscapulohumeral muscular dystrophy. Neurology 1997; 48: A194–A195. Google Scholar 17Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988; 53: 219–228. 10.1016/0092-8674(88)90383-2 CASPubMedWeb of Science®Google Scholar 18Lefaucheur JP, Pastoret C, Sebille A. Phenotype of dystrophinopathy in old mdx mice. Anat Rec 1995; 242: 70–76. 10.1002/ar.1092420109 CASPubMedWeb of Science®Google Scholar 19Maltin CA, Reeds PJ, Delday MI, Hay SM, Smith FG, Lobley GE. Inhibition and reversal of denervation-induced atrophy by the β-agonist growth promoter, clenbuterol. Biosci Rep 1986; 6: 811–818. 10.1007/BF01117104 CASPubMedWeb of Science®Google Scholar 20Mongini T, Ghigo D, Doriguzzi C, Bussolino F, Pescarmona G, Pollo B, Schiffer D, Bosia A. Free cytoplasmic Ca++ at rest and after cholinergic stimulus is increased in cultured muscle cells from Duchenne muscular dystrophy patients. Neurology 1988; 38: 476–480. 10.1212/WNL.38.3.476 CASPubMedWeb of Science®Google Scholar 21Pastoret C, Sebille A. Further aspects of muscular dystrophy in mdx mice. Neuromusc Disord 1993; 3: 471–475. 10.1016/0960-8966(93)90099-6 CASPubMedWeb of Science®Google Scholar 22Pastoret C, Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci 1995; 129: 97–105. 10.1016/0022-510X(94)00276-T CASPubMedWeb of Science®Google Scholar 23Reeds PJ, Hay SM, Dorwood PM, Palmer RM. Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis. Br J Nutr 1986; 56: 249–258. 10.1079/BJN19860104 CASPubMedWeb of Science®Google Scholar 24Sacco P, Jones DA, Dick JRT, Vrbova G. Contractile properties and susceptibility to exercise-induced damage of normal and mdx mouse tibialis anterior muscle. Clin Sci 1992; 82: 227–236. 10.1042/cs0820227 CASPubMedWeb of Science®Google Scholar 25Sandri M, Carraro U, Podhorska-Okolov M, Rizzi C, Arslan P, Monti D, Franceschi C. Apoptosis, DNA damage and ubiquitin expression in normal and mdx muscle fibers after exercise. FEBS Lett 1995; 373: 291–295. 10.1016/0014-5793(95)00908-R CASPubMedWeb of Science®Google Scholar 26Sharma KR, Mynhier MA, Miller RG. Cyclosporine increases muscular force generation in Duchenne muscular dystrophy. Neurology 1993; 43: 527–532. 10.1212/WNL.43.3_Part_1.527 CASPubMedWeb of Science®Google Scholar 27Squier MK, Cohen JC. Calpain, an upstream regulator of thymocyte apoptosis. J Immunol 1997; 158: 3690–3697. 10.4049/jimmunol.158.8.3690 CASPubMedWeb of Science®Google Scholar 28Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991; 352: 536–539. 10.1038/352536a0 CASPubMedWeb of Science®Google Scholar 29Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994; 83: 113–118. 10.1182/blood.V83.1.113.113 CASPubMedWeb of Science®Google Scholar 30Turner PR, Westwood T, Regen CM, Steinhardt RA. Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. Nature 1988; 335: 735–738. 10.1038/335735a0 CASPubMedWeb of Science®Google Scholar 31Vilquin JT, Brussee V, Asselin I, Kinoshita I, Gingras M, Tremblay JP. Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. Muscle Nerve 1998; 21: 567–576. 10.1002/(SICI)1097-4598(199805)21:5 3.0.CO;2-6 CASPubMedWeb of Science®Google Scholar 32Wakeford S, Watt DJ, Partridge TA. X-Irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. Muscle Nerve 1991; 14: 42–50. 10.1002/mus.880140108 CASPubMedWeb of Science®Google Scholar 33Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 1988; 52: 503–513. 10.1016/0092-8674(88)90463-1 CASPubMedWeb of Science®Google Scholar 34Weller B, Karpati G, Carpenter S. Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci 1990; 100: 9–13. 10.1016/0022-510X(90)90005-8 CASPubMedWeb of Science®Google Scholar 35Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S, Kobayashi J, Yamazaki F, Tanaka H, Inagaki N, Nagai H. Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology 1997; 54; 144–152. 10.1159/000139481 CASPubMedWeb of Science®Google Scholar 36Zeman RJ, Ludemann R, Etlinger JD. Clenbuterol, a β2-agonist, retards atrophy in denervated muscles. Am J Physiol 1987; 252: E152–E155. CASPubMedWeb of Science®Google Scholar 37Zeman RJ, Ludemann R, Easton TG, Etlinger JD. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a β2receptor agonist. Am J Physiol 1988; 254: E726–E732. CASPubMedWeb of Science®Google Scholar 38Zeman RJ, Hirschman A, Hirschman ML, Guo G, Etlinger JD. Clenbuterol, a β2receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol 1991; 261: E285–E289. 10.1152/ajpendo.1991.261.2.E285 CASPubMedWeb of Science®Google Scholar 39Zeman RJ, Zhang Y, Etlinger JD. Clenbuterol, a β2-adrenoceptor agonist, reduces scoliosis due to partial transection of rat spinal cord. Am J Physiol 1997; 272: E712–E715. 10.1152/ajpendo.1997.272.4.E712 CASPubMedWeb of Science®Google Scholar 40Zeman RJ, Zhang Y, Etlinger JD. Clenbuterol, a β2-agonist, retards wasting and loss of contractility in irradiated dystrophic mdx muscle. Am J Physiol 1994; 267: C865–C868. 10.1152/ajpcell.1994.267.3.C865 CASPubMedWeb of Science®Google Scholar 41Zeman RJ, Zhang Y, Etlinger JD. Control of muscle atrophy by clenbuterol following spinal cord injury at different levels. J Spinal Cord Med 1995; 18: 283. Google Scholar Citing Literature Volume23, Issue4April 2000Pages 521-528 ReferencesRelatedInformation